A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Study sponsor: Alumis Inc · ALMS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-06-29Actual
Enrollment · participants228Actual
Source updated2025-06-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.